New directions in the development of antidepressants: the interface of neurobiology and psychiatry
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
There have been considerable advances in neurobiology in recent years that are providing new directions for the development of novel classes of antidepressants. For example, the finding that corticotropin-releasing factor (CRF) is hypersecreted in depressed patients and mediates certain symptoms of depression has led to the development of specific antagonists of the CRF(1) receptor. These are expected to prove highly effective for the treatment of mood and anxiety disorders. Another related avenue of research is based on evidence that cortisol is integral to the pathophysiology of major depression with psychotic features. One alternative for treating this subtype of affective disorder is, therefore, to block the action of glucocorticoids using a receptor antagonist such as mifepristone. These are just two of the many new directions that will likely lead to the development of antidepressants in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485 · cited 2×
“…fluid (CSF) concentrations of CRF in untreated depressed patients and suicide victims, but not in patients with other psychiatric disorders or in healthy volunteers (Arató et al., 1986; Arató et al., 1989; Bánki et al., 1987; Bánki et al., 1992a; France et al., 1988; Nemeroff et al., 1984).”
BackgroundResultSelf-citationDunn, A. J., & Berridge, C. W. (1990) · Brain Research Reviews · doi:10.1016/0165-0173(90)90012-d · Cited by 1,352
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 1×
“…with psychotic major depression have a considerably higher rate of dexamethasone nonsuppression (i.e. cortisol hypersecretion due to hyperactivity of the pituitary–adrenal axis) than patients with non-psychotic major depression or healthy controls (Evans et al., 1983; Nelson and Davis, 1997).”
BackgroundRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282
Banki, C. M., Karmacsi, L., Bissette, G., & Nemeroff, C. B. (1992) · European Neuropsychopharmacology · doi:10.1016/0924-977x(92)90019-5 · Cited by 149 · cited 6×
“This elevation in CRF secretion appears to be statedependent as it can be normalized by successful treatment with a variety of antidepressants (fluoxetine, paroxetine, venlafaxine, desipramine and amitriptyline) and electroconvulsive therapy (ECT) (Bánki et al., 1992b; Veith et al., 1993; Nemeroff et al., 1991).”
BackgroundResultInfluentialSelf-citation
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Merali, Z., Du, L., Hrdina, P., Palkovits, M., Faludi, G., Poulter, M. O., & Anisman, H. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4734-03.2004 · Cited by 400
Neuropeptides: opportunities for drug discovery
Hökfelt, T., Bartfai, T., & Bloom, F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00482-4 · Cited by 328
Appelhof, B. C., Huyser, J., Verweij, M., Brouwer, J. P., van Dyck, R., Fliers, E., Hoogendijk, W. J. G., Tijssen, J. G. P., Wiersinga, W. M., & Schene, A. H. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.09.008 · Cited by 154
Mood disorders medications: predictors of nonadherence – review of the current literature
Pompili, M., Venturini, P., Palermo, M., Stefani, H., Seretti, M. E., Lamis, D. A., Serafini, G., Amore, M., & Girardi, P. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.811976 · Cited by 120
Toufexis, D. J., Davis, C., Hammond, A., & Davis, M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1386-04.2004 · Cited by 86
Howell, M. P., & Muglia, L. J. (2006) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2006.05.001 · Cited by 46
Depression and anxiety in supportive oncology
Li, M., Boquiren, V., Lo, C., & Rodin, G. (2011) · Supportive Oncology · doi:10.1016/b978-1-4377-1015-1.00052-7 · Cited by 32
Krohg, K., Hageman, I., & Balslev Jørgensen, M. (2008) · Nordic Journal of Psychiatry · doi:10.1080/08039480801983588 · Cited by 18
Metadata
- Authors
- Nemeroff, C. B.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2002
- Volume
- 17
- Issue
- S1
- Pages
- S13-S16
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1974466404
- Cited by
- 45
- References
- 5
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.